Effects of NSAIDs and non-NSAID Analgesics on Osteoarthritis Outcomes

NSAID 和非 NSAID 镇痛药对骨关节炎结局的影响

• 批准号: 9765134
• 负责人: S. Reza Jafarzadeh
• 金额: $ 8.25万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9765134
• 关键词: Accounting; Address; Adherence; Adult; Adverse effects; Affect; American; Analgesics; Anti-inflammatory; Arthritis; Body mass index; Cessation of life; Clinical; Complex; Data; Decision Making; Degenerative polyarthritis; Deterioration; Diagnostic radiologic examination; Disease; Disease Outcome; Disease Progression; Drug usage; Drug user; GTP-Binding Protein alpha Subunits, Gs; Goals; Growth Inhibitors; Hip region structure; Image; Indomethacin; Inflammation; Injury; Intervention; Joints; Knee; Knee Osteoarthritis; Knowledge; Lead; Long-Term Effects; Longitudinal Studies; Longterm Follow-up; Medical; Methods; Modeling; Modernization; Nerve; Non-Steroidal Anti-Inflammatory Agents; Obesity; Observational Study; Outcome; Pain; Patient-Focused Outcomes; Patients; Persons; Pharmaceutical Preparations; Property; Rehabilitation therapy; Replacement Arthroplasty; Research Methodology; Rheumatism; Risk; Structure; Time; Work; adverse outcome; aging population; burden of illness; chronic pain; chronic pain relief; cohort; design; disability; disorder risk; epidemiology study; experience; follow-up; high risk; improved functioning; insight; knee pain; knee replacement arthroplasty; novel; optimal treatments; pain reduction; pain relief; randomized trial; study population; temporal measurement; treatment choice; treatment strategy; years lived with disability

PROJECT SUMMARY/ABSTRACT Osteoarthritis affected at least 27 million US adults in 2008, and that number is expected to rise to about 50 million by 2020 because of growing obesity and the aging population. A leading cause of disability in the world, osteoarthritis has contributed to about 30% increase in Years Lived with Disability (YLDs) according to Global Burden of Disease 2016 estimates. Yet, no definitive treatment exists for osteoarthritis. The number of total knee replacements, the ultimate end-point of osteoarthritis when medical and rehabilitative efforts fail, is expected to rise to 3.5 million annually by 2030. Medical interventions so far have focused on pain-relieving interventions, with nonsteroidal anti-inflammatory drugs (NSAIDs) and non-NSAID analgesics being the primary non-surgical treatment choices. Despite the widespread use of these medications, their potential adverse effects on the disease in the long-term is not well characterized. Specifically, limited data exist on how reducing chronic pain in patients suffering from osteoarthritis would affect the risk of disease progression or the risk of knee replacement. The long-term goal of this project is to facilitate decision making for clinicians and patients of a more optimal treatment strategy for chronic pain relief interventions in osteoarthritis. The central hypothesis of this proposal is that non-NSAID analgesics users, compared to NSAIDs users, are at an increased risk of long- term osteoarthritis adverse outcomes, including disease progression (determined radiographically) and knee replacement. While both types of pain relievers may, with effective pain relief, produce higher levels of injurious activity, only NSAIDs may mitigate this damage by reducing intra-articular inflammation. Non-NSAID analgesics, unlike NSAIDs, lack anti-inflammatory properties that could reduce intra-articular inflammation sufficiently enough to minimize potential damage. We propose to use the Osteoarthritis Initiative (OAI) cohort, a longitudinal study of persons with or at risk of knee osteoarthritis studied annually over 10 years, with extensive clinical, imaging, and medication use data. Our aims are: to characterize the time-varying effects on osteoarthritis outcomes of 1) non-NSAID pure analgesics, 2) prescription NSAIDs, and 3) to compare the effects of non-NSAID analgesics with those from NSAIDs. The contribution of this work is significant because these two types of medications are among the most widely used for osteoarthritis. Our novel analytic approach is a departure from the traditional approaches of a restrictive definition of exposure that did not allow medication use to be intermittent (i.e. time-varying) or did not allow treatment switching. Unlike time-invariant approaches that were indifferent to changes in pain, our time-varying approach will allow us to account for time-dependent effect of pain, the main indicator for intervention or treatment switching. Our work will provide new evidence about effects of widely used medication of disease outcomes and will inform treatment choices.

项目总结/文摘